In the Spotlight - Large pharmaceutical firms are looking hard at buying smaller, younger biotech and pharma companies and are willing to part with big bucks to swing the deals. J&J's (USD)2.4 billion acquisition of Scios epitomizes the trend. The objective: Add products to the pipeline at a time when the buyer's own R&D efforts are slow in paying off.
|Year of Publication:||
|Type of Publication:||Article|
|Title record from database:|| OLC-SSG Economic Sciences|
|Availability:||More access options|
|More options (other):|
|Description not available.|